Subarachnoid Hemorrhage Trials: Cutting, Sliding, or Keeping mRS Scores and WFNS Grades.

The generation of rigorous evidence to inform the management of patients with aneurysmal subarachnoid hemorrhage (SAH) has lagged other types of acute strokes. The reason for this lag is multifactorial-one being that SAH has the lowest incidence of all forms of stroke. However, the paucity of SAH randomized controlled trials (RCTs) can also be self-exacerbating. Rather than adopting existing trial designs and biostatistical methods, it forces new investigators to craft these anew. Here, we provide a basic biostatistical guide for investigators to navigate two foundational dilemmas in designing large-scale SAH RCTs.